InfuSystem Holdings Inc

INFU remains in a Stage 4 decline with successive lower highs and lower lows. Declining short- and intermediate-term moving averages are acting as resistance, and price has failed to reclaim the 9/21/50 EMA band. Short-term momentum shows no exhaustion signal, with price below the EMAs and RSI above oversold levels. The medium-term bias is bearish, and execution timing is favorable. Sell Now into rallies toward the EMA resistance zone, invalidated only by a sustained reclaim and acceptance above the key moving averages.

• ↑6–8% annual revenue growth guided despite $7.1 M GE contract drag
• ↑Adjusted EBITDA margin rose to 18.9%, targeting low-to-mid-20% range
• ↓GE contract revision drives $7.1 M annual net revenue loss; Q1 rev down 3% to $33.7 M